Bajuri M Y, Md-Noorpi N H, Yin M K, Azman I, Adib-Adham N S
Department of Orthopaedics and Traumatology, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
Department of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
Malays Orthop J. 2024 Mar;18(1):66-72. doi: 10.5704/MOJ.2403.009.
The objective of this case series is to investigate the efficacy and safety of intravenous infusion of Pamidronate, a second generation bisphosphonate, in the treatment of active Charcot arthropathy.
All patients with active Charcot arthropathy treated at the medical centre from 1 January 2013 to 30 June 2020 were included in the study. Efficacy outcome was evaluated based on time to consolidate findings observed through radiographic examination, while safety outcome was evaluated based on the incidence of adverse event (AE) occurrence.
A total of 81 patients (37 male, 44 female) diagnosed with active Charcot arthropathy were included. 64.2% of patients were at stage 1 of Charcot arthropathy whereas 35.8% were at stage 2. The mean time to consolidate for stage 1 and stage 2 was 6.50 ± 4.21 months and 3.63 ± 2.92 months respectively (p-value = 0.139). No significant association was observed between gender, ethnicity and disease stage with the consolidation time (p-value >0.05). The rate of AE incidence was 2.5%, observed in 2 patients who developed a fever during the treatment. No other serious AE was observed in the study.
Intravenous Pamidronate infusion is a safe and effective treatment option for Charcot arthropathy.
本病例系列的目的是研究第二代双膦酸盐帕米膦酸静脉输注治疗活动期夏科氏关节病的疗效和安全性。
纳入2013年1月1日至2020年6月30日在该医疗中心接受治疗的所有活动期夏科氏关节病患者。疗效结果根据通过影像学检查观察到的骨愈合时间进行评估，而安全性结果根据不良事件（AE）发生的发生率进行评估。
共纳入81例诊断为活动期夏科氏关节病的患者（男性37例，女性44例）。64.2%的患者处于夏科氏关节病1期，35.8%处于2期。1期和2期的平均骨愈合时间分别为6.50±4.21个月和3.63±2.92个月（p值=0.139）。未观察到性别、种族和疾病分期与骨愈合时间之间存在显著关联（p值>0.05）。AE发生率为2.5%，在2例治疗期间出现发热的患者中观察到。该研究中未观察到其他严重AE。
帕米膦酸静脉输注是治疗夏科氏关节病的一种安全有效的治疗选择。
